CRESCENT BIOPHARMA, INC. (CBIO) Profit Margins
Over the twelve months to 2026-06-30, CRESCENT BIOPHARMA, INC. (CBIO) had operating margin -1417.7%, net margin -808.1%, free cash flow margin -619.5%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CBIOCRESCENT BIOPHARMA, INC.Follow CBIO — free
—
Price chart with a free account
- Market cap
- 476.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -74.1% | -63.7% | -172505.3% | -506.8% | -5470.7% | -63204.4% | -392752.9% | -1407.5% | -1417.7% | |
| Net margin | -74.0% | -63.6% | -171945.1% | -502.1% | -5469.0% | -62251.7% | -368994.2% | -1419.6% | -808.1% | |
| FCF margin | -29.9% | -42.4% | -164516.0% | -386.8% | -4958.3% | -62055.6% | -349013.0% | -668.1% | -619.5% |
USD millions · SEC XBRL
CRESCENT BIOPHARMA, INC. — questions
- What is CRESCENT BIOPHARMA, INC.'s operating margin?
- -1417.7% over the twelve months to 2026-06-30.
- What is CRESCENT BIOPHARMA, INC.'s net profit margin?
- -808.1% over the twelve months to 2026-06-30.
Every figure on this page comes from CRESCENT BIOPHARMA, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.